Stéphane Bancel, Moderna CEO (Photo by Michael Brochstein/Sipa USA)(Sipa via AP Images)
November 7, 2024 06:30 AM ESTUpdated 06:48 AM
People
Pharma

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Max Bayer

Pharma Reporter

Mod­er­na re­vealed the con­se­quences of its late start in the mar­ket for RSV vac­cines, re­port­ing just $10 mil­lion in third-quar­ter sales from the new shot …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times